The ExocordOA consortium has announced the launch of a 5-year, €13 million (US$17.2 million) project, funded by Horizon Europe, to advance extracellular vesicle-enriched secretome therapies toward clinical use,…
The ExocordOA consortium has announced the launch of a 5-year, €13 million (US$17.2 million) project, funded by Horizon Europe, to advance extracellular vesicle-enriched secretome therapies toward clinical use, with an initial focus on osteoarthritis.
Source disclosure
This is a source-linked briefing. Read the original report from Bioworld .